Skip to main content

Advertisement

Table 2 Characteristics of the studies included in the meta-analysis

From: A meta-analysis and systematic review: adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma

Study Group Cases Average age (ys) Male rate (%) Tumor size (cm) No. of tumor≥2 (%) Cirrhosis (%) Child-Pugh (%,A/B) Hepatic virus Therapy
Kubo S (2002) Interferon 15 61.9 100.0 2.5 0 46.7 73.3/26.7 HCV Surgical resection
Placebo 15 60.0 100.0 2.6 0 52.2 80.0/20.0
Shiratori Y (2003) Interferon 49 61.0 71.4 2.2 34.7 100.0 -- HCV Surgical resection
Placebo 25 63.0 68.0 2.3 36.0 100.0 --
Lin SM (2004) Interferon 20 61.5 80.0 2.2 15.0 90.0 85.0/15.0 HBV/ HCV TACE
Placebo 10 59.0 70.0 2.5 20.0 100.0 90.0/10.0
Piao CY (2005) Interferon 30 59 76.7 2.3 23.3 13.0 60.0/36.7 HBV/ HCV Ablation/TACE/surgical resection
Placebo 40 58 72.5 2.5 17.5 23.0 55.0/42.5
Mazzaferro V (2006) Interferon 76 65.0 80.3 3.4 22.4 94.0 92.1/7.9 HCV Surgical resection
Placebo 74 67.0 68.9 3.2 25.7 88.0 94.6/5.4
Sun HC (2006) Interferon 118 52.2 89.8 4.3 13.6 83.1 -- HBV Surgical resection
Placebo 118 50.4 86.4 4.9 12.7 88.1 --
Lo CM (2007) Interferon 40 49.0 77.5 5.5 17.5 47.5 -- HBV/ HCV Surgical resection
Placebo 40 54.0 85.0 5.7 27.5 47.5 --
Li M (2009) Interferon 108 50.3 71.3 4.9 54.6 100.0 90.7/9.3 HBV TACE
Placebo 108 49.2 68.5 4.8 54.6 100.0 91.7/8.3
Li N (2010) Interferon 43 53.2 72.5 3.2 37.2 88.0 85.0/15.0 HBV TACE
Placebo 36 51.2 71.3 3.4 37.2 88.0 85.0/15.0
Ishikawa (2012) Interferon 29 59.0 83.2 2.3 13.5 100.0 -- HCV TACE
  Placebo 25 58.7 81.2 2.5 17.4 100.0 --   
  1. Abbreviation: TACE trans-catheter arterial chemoembolization.